MCID: TXC002
MIFTS: 55

Toxic Encephalopathy

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Toxic Encephalopathy

MalaCards integrated aliases for Toxic Encephalopathy:

Name: Toxic Encephalopathy 12 49 14
Neurotoxicity Syndromes 72 49 41
Neurotoxicity 12 50
Neurotoxicity Syndrome 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3602
MeSH 41 D020258
NCIt 46 C27961
SNOMED-CT 64 19466003
ICD10 32 G92
UMLS 69 C0235032

Summaries for Toxic Encephalopathy

NINDS : 50 Neurotoxicity occurs when the exposure to natural or manmade toxic substances (neurotoxicants) alters the normal activity of the nervous system. This can eventually disrupt or even kill neurons, key cells that transmit and process signals in the brain and other parts of the nervous system. Neurotoxicity can result from exposure to substances used in chemotherapy, radiation treatment, drug therapies, and organ transplants, as well as exposure to heavy metals such as lead and mercury, certain foods and food additives, pesticides, industrial and/or cleaning solvents, cosmetics, and some naturally occurring substances. Symptoms may appear immediately after exposure or be delayed. They may include limb weakness or numbness; loss of memory, vision, and/or intellect; headache; cognitive and behavioral problems; and sexual dysfunction. Individuals with certain disorders may be especially vulnerable to neurotoxicants.

MalaCards based summary : Toxic Encephalopathy, also known as neurotoxicity syndromes, is related to alzheimer disease and hearing loss, noise-induced. An important gene associated with Toxic Encephalopathy is HMOX1 (Heme Oxygenase 1), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Circadian entrainment. The drugs Oxaliplatin and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include brain, skin and testes, and related phenotypes are Decreased caspase 3/7 activity and behavior/neurological

Disease Ontology : 12 A nervous system disease that results from exposure to neurotoxicants and is characterized by an altered mental status, memory loss, and visual problems.

Wikipedia : 72 Neurotoxicity is a form of toxicity in which a biological, chemical, or physical agent produces an... more...

Related Diseases for Toxic Encephalopathy

Diseases related to Toxic Encephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Related Disease Score Top Affiliating Genes
1 alzheimer disease 30.7 ACHE APP BACE1 BDNF CASP3 GRIN2A
2 hearing loss, noise-induced 30.2 GSTM1 GSTT1 TH
3 neuroblastoma 30.2 APP BACE1 BDNF CASP3 NGF PRNP
4 dementia 29.6 ACHE APP BACE1 BDNF PRNP
5 phenylketonuria 11.1
6 wernicke-korsakoff syndrome 11.1
7 hepatic encephalopathy 11.1
8 hypermanganesemia with dystonia 11.0
9 alzheimer disease 2 10.8
10 alzheimer disease mitochondrial 10.8
11 alzheimer disease 4 10.8
12 alzheimer disease 3 10.8
13 alzheimer disease 9 10.8
14 alzheimer disease 18 10.8
15 alzheimer disease 19 10.8
16 kernicterus 10.8
17 fetal methylmercury syndrome 10.8
18 hyperbetaalaninemia 10.8
19 encephalopathy 10.7
20 sister chromatid exchange, frequency of 10.6 EPHX1 GSTM1 GSTT1
21 acute lymphoblastic leukemia, childhood 10.5 ABCB1 GSTM1 GSTT1
22 varicocele 10.5 CASP3 GSTM1 GSTT1
23 deafness, autosomal recessive 74 10.5 BACE1 CASP3
24 oral cancer 10.5 CASP3 GSTM1 GSTT1
25 neuronitis 10.5
26 lesion of sciatic nerve 10.5 NGF TRPV1
27 acute lymphocytic leukemia 10.4 ABCB1 GSTM1 GSTT1
28 neonatal hypoxic and ischemic brain injury 10.4 BDNF TH
29 paine syndrome 10.4 BDNF NGF TRPV1
30 akinetic mutism 10.4 PRNP SLC6A3
31 tobacco addiction 10.4 GSTM1 GSTT1 SLC6A3
32 isolated cleft lip 10.4 GSTM1 GSTT1
33 cerebral amyloid angiopathy, cst3-related 10.4 APP BACE1 PRNP
34 interstitial cystitis 10.4 BDNF NGF TRPV1
35 tendinosis 10.4 ACHE BDNF TH
36 personality disorder 10.4 BDNF MAOB SLC6A3
37 substance dependence 10.4 BDNF GSTM1 SLC6A3
38 pure autonomic failure 10.4 ACHE MAOB TH
39 specific developmental disorder 10.4 BDNF SLC6A3 TRPV1
40 nervous system cancer 10.4 BACE1 CASP3 NGF
41 lesch-nyhan syndrome 10.4 APP NGF SLC6A3
42 status epilepticus 10.4 BDNF CASP3 GRIN2B
43 restless legs syndrome 10.3 HMOX1 MAOB SLC6A3 TH
44 hypoganglionosis 10.3 ACHE TH
45 ischemia 10.3 APP CASP3 HMOX1 TRPV1
46 aphasia 10.3 APP GRIN2A PRNP
47 vascular dementia 10.3 ACHE APP PRNP
48 synucleinopathy 10.3 APP MAOB SLC6A3 TH
49 cerebral hemorrhage 10.3 APP PRNP
50 major depressive disorder 10.2 ABCB1 BDNF GRIN2B SLC6A3

Graphical network of the top 20 diseases related to Toxic Encephalopathy:



Diseases related to Toxic Encephalopathy

Symptoms & Phenotypes for Toxic Encephalopathy

GenomeRNAi Phenotypes related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased caspase 3/7 activity GR00318-A 9.02 APP BACE1 CASP3 GRIN2A GRIN2B

MGI Mouse Phenotypes related to Toxic Encephalopathy:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.38 ACHE CASP3 APP GRIN2A BACE1 ABCB1
2 homeostasis/metabolism MP:0005376 10.31 ACHE CASP3 APP EPHX1 BACE1 ABCB1
3 growth/size/body region MP:0005378 10.25 BDNF ACHE CASP3 APP BACE1 ABCB1
4 cellular MP:0005384 10.23 BDNF CASP3 APP BACE1 ABCG2 PRNP
5 nervous system MP:0003631 10.13 ACHE CASP3 APP BACE1 ABCB1 ABCG2
6 integument MP:0010771 10.11 CASP3 APP BACE1 ABCG2 BDNF GRIN2A
7 no phenotypic analysis MP:0003012 9.93 ACHE CASP3 APP BACE1 ABCB1 ABCG2
8 muscle MP:0005369 9.92 ACHE CASP3 APP BACE1 NGF PRNP
9 normal MP:0002873 9.61 BDNF APP BACE1 ABCG2 NGF PRNP
10 taste/olfaction MP:0005394 8.92 BDNF CASP3 SLC6A3 TRPV1

Drugs & Therapeutics for Toxic Encephalopathy

Drugs for Toxic Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 462)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 43805 6857599 5310940 9887054
2
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
3
Fluorouracil Approved Phase 4,Phase 2,Phase 3 51-21-8 3385
4
Colistin Approved Phase 4 1066-17-7, 1264-72-8 5311054
5
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3 76-42-6 5284603
6
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
7
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
8
Ethanol Approved Phase 4,Phase 2 64-17-5 702
9
Lacosamide Approved Phase 4 860352-01-8, 175481-36-4 219078
10
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 1,Early Phase 1,Not Applicable 38396-39-3, 2180-92-9 2474
11
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 51-43-4 5816
12
Levobupivacaine Approved, Investigational Phase 4,Not Applicable 27262-47-1 92253
13 Racepinephrine Approved Phase 4,Phase 3,Not Applicable 329-65-7
14
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 175805 71273
15
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
16
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
17
Desflurane Approved Phase 4 57041-67-5 42113
18
Isoflurane Approved, Vet_approved Phase 4,Phase 3 26675-46-7 3763
19
Sevoflurane Approved, Vet_approved Phase 4,Phase 3 28523-86-6 5206
20
Basiliximab Approved, Investigational Phase 4 179045-86-4, 152923-56-3
21
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
22
Mycophenolate mofetil Approved, Investigational Phase 4,Not Applicable 128794-94-5 5281078
23
Mycophenolic acid Approved Phase 4,Not Applicable 24280-93-1 446541
24
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
25
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
26
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
27
Gabapentin Approved, Investigational Phase 4,Phase 3 60142-96-3 3446
28
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3 56-12-2 119
29
Norepinephrine Approved Phase 4,Phase 3,Not Applicable 51-41-2 439260
30
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
31
Lamotrigine Approved, Investigational Phase 4,Phase 3 84057-84-1 3878
32 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
33
Cobicistat Approved Phase 4,Not Applicable 1004316-88-4
34
Emtricitabine Approved, Investigational Phase 4,Not Applicable 143491-57-0 60877
35
alemtuzumab Approved, Investigational Phase 4,Phase 1,Phase 2 216503-57-0
36
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
37
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 76631-46-4, 113775-47-6 5311068 56032 68602
38
Lorazepam Approved Phase 4 846-49-1 3958
39
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
40
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
41
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
42
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
43
Ondansetron Approved Phase 4 99614-02-5 4595
44
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
45
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
46
Everolimus Approved Phase 4,Phase 1,Phase 2 159351-69-6 6442177
47
Sirolimus Approved, Investigational Phase 4,Phase 1,Phase 2 53123-88-9 46835353 6436030 5284616
48
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
49
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
50
Abacavir Approved, Investigational Phase 4 136470-78-5 441300 65140

Interventional clinical trials:

(show top 50) (show all 376)

# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia Unknown status NCT00837707 Phase 4 aripiprazole
3 OPTIMOX1 in Chinese mCRC Patients Unknown status NCT01023633 Phase 4 Oxaliplatin, LV, 5-FU
4 Colistin Pharmacokinetics in Continuous Renal Replacement Therapy Unknown status NCT02081560 Phase 4 Colistin
5 BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients Completed NCT02051062 Phase 4
6 Botulism Outbreak in Thailand (Episode II) Completed NCT00348426 Phase 4 Botulinum AntiToxin
7 Cognitive and Behavioral Effects of Lacosamide Completed NCT01175954 Phase 4 Lacosamide;Lacosamide
8 Thermal QST for Interscale Block Evaluation Completed NCT02271867 Phase 4
9 A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN) Completed NCT01675531 Phase 4 Targin
10 Recovery Following Desflurane Versus Sevoflurane for Outpatient Urologic Surgery in Elderly Females Completed NCT01310582 Phase 4 Desflurane;Sevoflurane
11 Taste, Smell and Chemotherapy (TASTY) Completed NCT01641172 Phase 4
12 Steroid Free Immunosuppression in Liver Transplantation Completed NCT00296244 Phase 4 Steroids;Basiliximab;Tacrolimus;Enteric-coated Mycophenolic acid (EC-MPA)
13 An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
14 Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs Completed NCT00438451 Phase 4 Levetiracetam;Carbamazepine;Lamotrigine
15 PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Recruiting NCT02864030 Phase 4 ERIBULIN MESYLATE
16 Optimum Thiamine Intervention (OpTIn) Trial Recruiting NCT02788552 Phase 4 Thiamine Hydrochloride
17 Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X) Recruiting NCT03163277 Phase 4 emtricitabine, darunavir/cobicistat, maraviroc
18 Neurotoxicity of Spinal Anesthesia With Ropivacaine and Bupivacaine Recruiting NCT03293472 Phase 4 Ropivacaine;Bupivacaine
19 Neurobiological and Cognitive Changes Following Exposure to Either Sevoflurane- or Propofol-based Anesthesia in Children Recruiting NCT03022240 Phase 4 Propofol;Sevoflurane;Ametop;Ondansetron
20 Lipids and Neurological Complications in Liver Transplantation Recruiting NCT02544919 Phase 4 SMOF lipid (SMOFLIPID) pre treatment
21 Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction Recruiting NCT01935128 Phase 4 Arm 1 Everolimus/Reduced dose tacrolimus
22 IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy Recruiting NCT02918409 Phase 4 Colistin;Tobramycin
23 A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/T Not yet recruiting NCT03067285 Phase 4 ELV/COBI/FTC/TAF;DTG/3TC/ABC + ELV/COBI/FTC/TAF
24 A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients Not yet recruiting NCT03461445 Phase 4 Envarsus;IR Tacrolimus
25 Analgesic Efficacy of Two Doses of Dexmedetomidine as Adjuncts to Lidocaine for Intravenous Regional Anesthesia Not yet recruiting NCT03399474 Phase 4 Dexmedetomidine Injection 0.25 ug/kg;Lidocaine;Nalbuphine;Paracetamol;Diclofenac sodium (Voltaren®);Dexmedetomidine Injection 0.5ug/kg
26 Pharmacokinetic Study of Adoport® (Tacrolimus) in Patients With de Novo Kidney Transplantation Not yet recruiting NCT03076151 Phase 4 Tacrolimus monohydrate (ADOPORT®)
27 L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer Terminated NCT00754767 Phase 4 L-carnitine L-tartrate
28 Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD) Terminated NCT01362205 Phase 4 Dexmedetomidine;Placebos
29 CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer Terminated NCT00129870 Phase 4 oxaliplatin
30 Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation Terminated NCT00656266 Phase 4 MMF (Cellcept);placebo
31 Pain Management After Total Shoulder Arthroplasty Terminated NCT03219983 Phase 4 Ropivacaine;liposomal bupivacaine
32 Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer Unknown status NCT02024438 Phase 3 monosialotetrahexosylganglioside Sodium
33 Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC Unknown status NCT02024412 Phase 3 monosialotetrahexosylganglioside Sodium
34 Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients Unknown status NCT00872352 Phase 3
35 Study of Opioid Rotation Versus Opioid Escalation in Patients With Moderate to Severe Cancer Pain Unknown status NCT02084355 Phase 3 oral oxycodone;oral hydromorphone;fentanyl patch
36 The Role of Glutamine for Preventing Oxaliplatin-Induced Peripheral Neuropathy Unknown status NCT02024191 Phase 3
37 Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery Unknown status NCT00274872 Phase 2, Phase 3 fluorouracil;leucovorin calcium;oxaliplatin
38 Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer Unknown status NCT00058474 Phase 3 capecitabine;fluorouracil;oxaliplatin
39 Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. Completed NCT00305188 Phase 3 Xaliproden (SR57746A);Placebo;Oxaliplatin;5-Fluorouracil;Leucovorin
40 XENOX – Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy Completed NCT00272051 Phase 3 SR57746A
41 Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer Completed NCT02311907 Phase 3 Carboplatin;Glutathione;Paclitaxel
42 Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer Completed NCT02486198 Phase 3 placebo;GM;oxaliplatin-based chemotherapy
43 Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer Completed NCT02468739 Phase 3 EC-T or TC plus GM1;EC-T or TC plus placebo
44 Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy Completed NCT01099449 Phase 3 calcium gluconate;magnesium sulfate;oxaliplatin
45 Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity Completed NCT01087658 Phase 3 Glutamine;Calcium and Magnesium
46 Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors Completed NCT00566852 Phase 3 Memantine
47 Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer Completed NCT00489411 Phase 3 duloxetine hydrochloride
48 Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients Completed NCT00471445 Phase 3 ketamine/amitriptyline NP-H cream
49 Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer Completed NCT00363129 Phase 3
50 Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery Completed NCT00316914 Phase 3 calcium gluconate;magnesium sulfate

Search NIH Clinical Center for Toxic Encephalopathy

Cochrane evidence based reviews: neurotoxicity syndromes

Genetic Tests for Toxic Encephalopathy

Anatomical Context for Toxic Encephalopathy

MalaCards organs/tissues related to Toxic Encephalopathy:

38
Brain, Skin, Testes, Lung, Liver, Bone, Colon

Publications for Toxic Encephalopathy

Articles related to Toxic Encephalopathy:

(show top 50) (show all 136)
# Title Authors Year
1
Routine fruit washing to prevent acute toxic encephalopathy - Authors' reply. ( 28807179 )
2017
2
Association of acute toxic encephalopathy with litchi consumption in an outbreak in Muzaffarpur, India, 2014: a case-control study. ( 28153514 )
2017
3
Myoclonic seizure prior to diagnosis of chronic toxic encephalopathy: a case report. ( 28173825 )
2017
4
Acute reversible toxic encephalopathy during capecitabine and oxaliplatin treatment. ( 29121830 )
2017
5
An easily overlooked cause of toxic encephalopathy: methylene blue in a patient on an SSRI. ( 28748330 )
2017
6
Routine fruit washing to prevent acute toxic encephalopathy. ( 28807178 )
2017
7
Odorless inhalant toxic encephalopathy in developing countries household: Gas geyser syndrome. ( 27114653 )
2016
8
Early Non-invasive Detection of Acute 1,2-Dichloroethane-induced Toxic Encephalopathy in Rats. ( 27815462 )
2016
9
Neem oil poisoning - Case report of an adult with toxic encephalopathy. ( 27728581 )
2016
10
Poster 349 Toxic Encephalopathy and Rash Resulting from Paradichlorobenzene Inhalation: A Case Report. ( 27673102 )
2016
11
A case of life-threatening acute kidney injury with toxic encephalopathy caused by Dioscorea quinqueloba. ( 25510780 )
2015
12
1,2-Dichloroethane-induced toxic encephalopathy: A case series with morphological investigations. ( 25743226 )
2015
13
Capecitabine: toxic encephalopathy. ( 26688902 )
2015
14
Toxic encephalopathy due to paradichlorobenzene toxicity: a case report and review of imaging characteristics. ( 26388394 )
2015
15
The effect of hemoperfusion on patients with toxic encephalopathy induced by silkworm chrysalis ingestion. ( 26610794 )
2015
16
Prolonged Toxic Encephalopathy following Accidental 4-Aminopyridine Overdose. ( 24822136 )
2014
17
Neem oil poisoning as a cause of toxic encephalopathy in an infant. ( 24522945 )
2014
18
Subacute reversible toxic encephalopathy related to treatment with capecitabine: a case report with literature review and discussion of pathophysiology. ( 24631316 )
2014
19
Toxic encephalopathy due to colchicine--Gloriosa superba poisoning. ( 24591648 )
2014
20
Toxic encephalopathy after exposure to azacitidine. ( 25224457 )
2014
21
L-asparaginase fatal toxic encephalopathy during consolidation treatment in an adult with acute lymphoblastic leukemia. ( 23961306 )
2013
22
Neem oil poisoning: Case report of an adult with toxic encephalopathy. ( 24339648 )
2013
23
Ethylene glycol toxic encephalopathy. ( 24347968 )
2013
24
MRI brain in monohalomethane toxic encephalopathy: A case report. ( 24347845 )
2013
25
Toxic encephalopathy. ( 23251840 )
2012
26
Lethal toxic encephalopathy due to childhood shigellosis or Ekiri syndrome. ( 22177366 )
2012
27
Toxic encephalopathy. ( 22362126 )
2012
28
Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report. ( 20926454 )
2011
29
Toxic encephalopathy. ( 21590623 )
2011
30
Establishment of a poisoned animal model of toxic encephalopathy induced by 1,2-dichloroethane. ( 21329570 )
2011
31
Toxic encephalopathy caused by occupational exposure to 1, 2-Dichloroethane. ( 20163807 )
2010
32
Toxic encephalopathy after taking dried seeds of Datura stramonium in two elderly subjects. ( 19702945 )
2009
33
Margosa (Kohomba) oil induced toxic encephalopathy following home remedy for intestinal worms. ( 20052860 )
2009
34
An unusual case of 4-aminopyridine toxicity in a multiple sclerosis patient: epileptic disorder or toxic encephalopathy? ( 19402572 )
2009
35
Acute toxic encephalopathy due to the ingestion of Rhus extract. ( 19570681 )
2009
36
High imipenem blood concentrations associated with toxic encephalopathy in a patient with mild renal dysfunction. ( 19596561 )
2009
37
Psychosocial and cognitive rehabilitation of patients with solvent-induced chronic toxic encephalopathy: a randomised controlled study. ( 18560254 )
2008
38
Chronic toxic encephalopathy caused by occupational solvent exposure. ( 18409195 )
2008
39
Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism. ( 19031955 )
2008
40
Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy. ( 17938643 )
2008
41
Severe reversible toxic encephalopathy induced by cisplatin in a patient with cervical carcinoma receiving combined radiochemotherapy. ( 17762922 )
2007
42
Neuroleptic malignant syndrome due to amisulpride in a patient with solvent-induced chronic toxic encephalopathy. ( 17762322 )
2007
43
Cognitive functioning in patients with suspected chronic toxic encephalopathy: evidence for neuropsychological disturbances after controlling for insufficient effort. ( 16484635 )
2006
44
Taurine induced toxic encephalopathy? ( 16844286 )
2006
45
Toxic encephalopathy and noise-induced hearing loss. ( 17851218 )
2006
46
Visual search and eye movements in patients with chronic solvent-induced toxic encephalopathy. ( 16765447 )
2006
47
Methadone intoxication in a child: toxic encephalopathy? ( 16970857 )
2006
48
Psychological distress and coping in women married to men with a diagnosis of solvent-induced chronic toxic encephalopathy. ( 16101264 )
2005
49
Education for men with solvent-induced chronic toxic encephalopathy and their spouses. ( 15950841 )
2005
50
Toxic encephalopathy induced by capecitabine. ( 15218302 )
2004

Variations for Toxic Encephalopathy

Expression for Toxic Encephalopathy

Search GEO for disease gene expression data for Toxic Encephalopathy.

Pathways for Toxic Encephalopathy

Pathways related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.37 APP BACE1 BDNF CASP3 GRIN2A GRIN2B
2
Show member pathways
12.6 ACHE GRIN2A GRIN2B MAOB SLC6A3 TH
3 12.05 BDNF CASP3 NGF TH
4 12.03 APP BACE1 GRIN2A GRIN2B NGF PRNP
5 11.97 BDNF CASP3 GRIN2B NGF
6 11.7 CASP3 SLC6A3 TH
7
Show member pathways
11.68 APP BDNF NGF
8 11.62 CASP3 GSTM1 GSTT1
9 11.6 ABCB1 ABCG2 EPHX1
10
Show member pathways
11.57 ABCG2 EPHX1 GSTM1 GSTT1
11 11.55 ABCB1 ABCG2 HMOX1
12 11.52 ABCG2 BDNF NGF TH
13
Show member pathways
11.38 APP BDNF CASP3 NGF
14
Show member pathways
11.33 ACHE SLC6A3 TH
15 11.19 APP BACE1 CASP3 PRNP
16 11.18 MAOB SLC6A3 TH
17
Show member pathways
11.17 BDNF GRIN2A GRIN2B MAOB SLC6A3 TH
18 11.12 ABCG2 GSTM1 GSTT1
19 10.99 EPHX1 GSTM1 GSTT1
20 10.96 ABCG2 EPHX1 HMOX1
21 10.8 ABCB1 GSTT1
22 10.77 MAOB TH
23 10.76 BDNF CASP3
24 10.73 ABCB1 ABCG2
25 10.68 ACHE TH
26 10.33 EPHX1 GSTM1

GO Terms for Toxic Encephalopathy

Cellular components related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.72 ACHE APP GRIN2A GRIN2B TRPV1
2 membrane raft GO:0045121 9.55 APP BACE1 CASP3 PRNP SLC6A3
3 neuron projection GO:0043005 9.43 APP GRIN2A GRIN2B SLC6A3 TH TRPV1
4 NMDA selective glutamate receptor complex GO:0017146 9.26 GRIN2A GRIN2B
5 cell surface GO:0009986 9.23 ABCB1 ACHE APP BACE1 GRIN2A GRIN2B

Biological processes related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.88 CASP3 GRIN2A HMOX1 NGF TRPV1
2 locomotory behavior GO:0007626 9.8 APP SLC6A3 TH
3 excitatory postsynaptic potential GO:0060079 9.79 GRIN2A GRIN2B TRPV1
4 response to wounding GO:0009611 9.76 ACHE CASP3 GRIN2A
5 response to organic cyclic compound GO:0014070 9.76 CASP3 EPHX1 SLC6A3 TH
6 learning GO:0007612 9.74 APP GRIN2A TH
7 positive regulation of long-term synaptic potentiation GO:1900273 9.65 APP GRIN2A
8 response to ethanol GO:0045471 9.65 GRIN2A GRIN2B MAOB SLC6A3 TH
9 response to corticosterone GO:0051412 9.64 MAOB TH
10 neurotrophin TRK receptor signaling pathway GO:0048011 9.64 CASP3 NGF
11 glutamate receptor signaling pathway GO:0007215 9.63 GRIN2A GRIN2B
12 cellular copper ion homeostasis GO:0006878 9.62 APP PRNP
13 negative regulation of activated T cell proliferation GO:0046007 9.62 CASP3 PRNP
14 neurotransmitter catabolic process GO:0042135 9.61 ACHE MAOB
15 cellular response to alkaloid GO:0071312 9.6 TH TRPV1
16 dopamine biosynthetic process GO:0042416 9.59 SLC6A3 TH
17 xenobiotic transport GO:0042908 9.58 ABCB1 ABCG2
18 cellular response to amyloid-beta GO:1904646 9.58 APP GRIN2A PRNP
19 negative regulation of long-term synaptic potentiation GO:1900272 9.56 APP PRNP
20 mating behavior GO:0007617 9.55 APP TH
21 dopamine catabolic process GO:0042420 9.54 MAOB SLC6A3
22 ionotropic glutamate receptor signaling pathway GO:0035235 9.54 APP GRIN2A GRIN2B
23 modulation of age-related behavioral decline GO:0090647 9.52 APP PRNP
24 calcium ion transmembrane import into cytosol GO:0097553 9.51 GRIN2A GRIN2B
25 neurotransmitter biosynthetic process GO:0042136 9.5 ACHE SLC6A3 TH
26 response to drug GO:0042493 9.5 ABCB1 ABCG2 CASP3 GRIN2A MAOB SLC6A3
27 neuron projection maintenance GO:1990535 9.49 APP PRNP
28 response to nicotine GO:0035094 9.46 CASP3 HMOX1 SLC6A3 TH
29 negative regulation of dendritic spine maintenance GO:1902951 9.43 GRIN2B PRNP
30 learning or memory GO:0007611 9.02 APP CASP3 GRIN2A GRIN2B PRNP

Molecular functions related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 amyloid-beta binding GO:0001540 9.5 ACHE BACE1 PRNP
2 dopamine binding GO:0035240 9.37 SLC6A3 TH
3 enzyme binding GO:0019899 9.35 APP BACE1 GSTM1 HMOX1 TH
4 xenobiotic transmembrane transporting ATPase activity GO:0008559 9.26 ABCB1 ABCG2
5 NMDA glutamate receptor activity GO:0004972 9.16 GRIN2A GRIN2B
6 glutamate-gated calcium ion channel activity GO:0022849 8.62 GRIN2A GRIN2B

Sources for Toxic Encephalopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....